{
    "data": [
        {
            "pmid": "27160474",
            "criteria": "Eligible studies included treatment na\u00efve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intravenous infusion of leucovorin (400 mg/m2) concomitantly with a 90-min intravenous infusion of irinotecan (180 mg/m2), followed by a bolus (400 mg/m2) and a 46-h continuous infusion (2,400 mg/m2) of 5-FU. The duration of a cycle is 2 weeks.(12)",
            "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527756"
        }
    ]
}